ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Price:
67.11 USD
0.89%
Market Closed
Updated:
May 3, 2024
ANI Pharmaceuticals Inc
Operating Income
|
ANI Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Operating Income
$48.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
6%
|
CAGR 10-Years
49%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is ANI Pharmaceuticals Inc's Operating Income?
Operating Income
48.1m
USD
48.1m
USD
Based on the financial report for Dec 31, 2023, ANI Pharmaceuticals Inc's Operating Income amounts to 48.1m USD.
What is ANI Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
49%
49%
You don't have any saved screeners yet
